Open Access

Reduced tissue and serum resistin expression as a clinical marker for esophageal squamous cell carcinoma

  • Authors:
    • Amos C. Hung
    • Yen-Yun Wang
    • Kun-Tsung Lee
    • Hung-Hsing Chiang
    • Yuk-Kwan Chen
    • Je-Kang Du
    • Chun-Ming Chen
    • Michael Yuanchien Chen
    • Kwei-Jing Chen
    • Stephen Chu-Sung Hu
    • Shyng-Shiou F. Yuan
  • View Affiliations

  • Published online on: September 10, 2021     https://doi.org/10.3892/ol.2021.13035
  • Article Number: 774
  • Copyright: © Hung et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Esophageal cancer is one of the most common malignancies and leading cause of cancer‑associated mortality worldwide. However, the molecular mechanisms underlying esophageal cancer progression and the development of clinical tools for effective diagnosis remain unclear. Resistin, which was originally identified as an adipose tissue‑secretory factor, has been associated with obesity‑related diseases, including certain types of cancer. Thus, the present study aimed to investigate the expression levels of resistin in tissue and serum specimens from patients with esophageal squamous cell carcinoma (ESCC) to determine the potential biological effects of resistin on ESCC cells. The results demonstrated that both tissue and serum resistin levels were significantly lower in patients with ESCC compared with healthy controls. In addition, resistin expression was positively associated with the body mass index of patients with ESCC. In vitro studies revealed that resistin inhibited the migratory ability of ESCC cells, while having no effect on ESCC cell proliferation. Taken together, these results suggest that resistin may have the potential to be developed into a clinical marker for ESCC. However, further studies are required to investigate resistin receptor expression and determine the potential involvement of resistin‑associated biological pathways, which may provide insight for future development of targeted therapies for resistin‑mediated ESCC.
View Figures
View References

Related Articles

Journal Cover

November-2021
Volume 22 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Hung AC, Wang Y, Lee K, Chiang H, Chen Y, Du J, Chen C, Chen MY, Chen K, Hu SC, Hu SC, et al: Reduced tissue and serum resistin expression as a clinical marker for esophageal squamous cell carcinoma. Oncol Lett 22: 774, 2021
APA
Hung, A.C., Wang, Y., Lee, K., Chiang, H., Chen, Y., Du, J. ... Yuan, S.F. (2021). Reduced tissue and serum resistin expression as a clinical marker for esophageal squamous cell carcinoma. Oncology Letters, 22, 774. https://doi.org/10.3892/ol.2021.13035
MLA
Hung, A. C., Wang, Y., Lee, K., Chiang, H., Chen, Y., Du, J., Chen, C., Chen, M. Y., Chen, K., Hu, S. C., Yuan, S. F."Reduced tissue and serum resistin expression as a clinical marker for esophageal squamous cell carcinoma". Oncology Letters 22.5 (2021): 774.
Chicago
Hung, A. C., Wang, Y., Lee, K., Chiang, H., Chen, Y., Du, J., Chen, C., Chen, M. Y., Chen, K., Hu, S. C., Yuan, S. F."Reduced tissue and serum resistin expression as a clinical marker for esophageal squamous cell carcinoma". Oncology Letters 22, no. 5 (2021): 774. https://doi.org/10.3892/ol.2021.13035